化學系89屆校友英偉文在抗腫瘤藥物研發方面取得傑出成就

       英偉文校友現為美國Synta制藥公司腫瘤藥物研發高級總監。他帶領團隊研發了肺癌治療藥物Ganetespib，一種熱休克蛋白90的抑制劑，現已處于臨床III期試驗階段。Ganetespib作為非常有希望的新型抗癌藥物，若其在臨床試驗中被證明有效，很有可能會給肺癌患者帶來福音。

英偉文校友1989年畢業于太阳集团app首页化學系，同年免試保送上海有機所攻讀碩士，在1992年碩士畢業後赴美，在克萊姆森大學獲得博士學位，然後分别在耶魯大學和紐約州立大學石溪分校進行有機合成和生物物理的博士後研究。他在2000年進入Synta公司并開始了研發之路。作為最新成果，這項藥物在2007年進入了臨床試驗階段，并且作為治療非小細胞肺癌的特效藥物接受了美國食品藥品管理局的直通車式審查，現正處于最後審批階段。

美國《C&EN》雜志對英偉文校友的成就給予了充分的肯定，“他們（英偉文校友和另兩位中國化學家）的發明不僅延長了患者的生命，還為他們所在的生物科技公司帶來了數以億計的收益。”

       備注：《C&EN》雜志是美國化學學會（ACS）出版的新聞周刊，緻力于關注化學化工界的最新事件。

 

C&EN封面

 

報道文章

附：英偉文校友簡介

Dr. Weiwen Ying is Synta Fellow at Synta Pharmaceuticals (Nasdaq SNTA) in Lexington MA. He initiated and championed the discovery and development of ganetespib, an Hsp90 inhibitor, which is being evaluated in multiple clinical trials including a Phase III trial in lung cancer. As a prolific drug hunter, his experience in drug development ranges from conception of scientific ideas to managing relations with physicians and academic collaborators. Dr. Ying has published >20 peer-review journal articles and also has >30 issued or pending patents. Recently Weiwen and his colleague have developed the HDC (Hsp90-inhibitor Drug Conjugates) platform technology which has tremendous potential in creating an exciting, new class of anti-cancer therapies.

Prior to joining Synta in 2000, Dr. Ying was a postdoctoral fellow at SUNY Stony Brook and Yale University. He obtained Ph.D. in Organic Chemistry from Clemson University and M.S. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science. He received his undergraduate degree from Sun Yat-sen University in Guangzhou, China.